Research programme: corona virus infections - Protinhi Therapeutics
Alternative Names: Pan-Corona - Protinhi Therapeutics; PanCoroNed - Protinhi TherapeuticsLatest Information Update: 12 Jun 2023
At a glance
- Originator Protinhi Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Viral protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Coronavirus infections; COVID 2019 infections
Most Recent Events
- 12 Jun 2023 Research programme: corona virus infections - Protinhi Therapeutics is available for licensing as of 12 June 2023. https://www.protinhi.com/rd/
- 30 Nov 2021 Research programme: corona virus infections - Protinhi Therapeutics is available for licensing as of 30 Nov 2021. https://www.protinhi.com/rd/
- 30 Nov 2021 Early research in Coronavirus infections in Netherlands (PO) before November 2021